FZ-AD005
Based on 1 Customer Validation
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.04%
- Masse moléculaire:154128 (average)
-
Stockage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Topoisomerase
More
Activité biologique
|
Topoisomerase I |
FZ-AD005 (1 μg/mL; 144 hours) exhibits a strong bystander killing effect, eliminating both DLL3-positive NCI-H82 cells and DLL3-negative Ramos cells in a Transwell coculture system[1].
FZ-AD005 (0.78-100 nmol/L human DLL3) exhibits high affinity binding to human DLL3 (Kd=58.3 pmol/L) and FcRn (Kd=29 nmol/L), but very low affinity for FcγRI, FcγRIIa, and FcγIIIa, when tested in a biolayer interferometry assay[1].
FZ-AD005 (100 μg/mL; 7 days) is highly stable in human plasma, with only ~0.7% DXd released after 7 days of incubation at 37°C[1].
FZ-AD005 (200 pmol; 48 hours) rapidly internalizes into DLL3-expressing cells within 30 minutes, traffics to lysosomes, and releases DXd in a time-dependent manner when tested over 48 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLL3-positive NCI-H82 cells, DLL3-negative Ramos cells
-
Concentration:1 μg/mL
-
Incubation Time:144 hours
-
Result:Effectively eliminated both NCI-H82 and Ramos cell populations in the coculture system.
Single intravenous administration of FZ-AD005 (1.5-6 mg/kg; intravenous injection; single dose) at doses of 1.5, 3 and 6 mg/kg induces complete tumor growth inhibition in male NOD/SCID mice inoculated with NCI-H660 NEPC xenografts[1].
FZ-AD005 (1-5 mg/kg; intravenous injection; once weekly; 2 total administrations) induces significant tumor growth inhibition in female BALB/c nude mice bearing NCI-H82 SCLC xenografts; at intravenous doses of 1, 3 and 5 mg/kg given once weekly for 2 total administrations, its TGI ranges from 76.52% to 97.13%[1].
FZ-AD005 (1.5-6 mg/kg; intravenous injection; single administration) induces potent to complete tumor growth inhibition in mice bearing SCLC LU-5236 PDX, with TGIs ranging from 98.51% to 100.00% across different dose groups on day 21 post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (female) with Small cell lung cancer[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.v.; single dose
-
Result:Achieved tumor growth inhibition (TGI) values of 86.21% (2.5 mg/kg), 94.53% (5 mg/kg), and 95.54% (10 mg/kg) compared to vehicle control.
Caused no obvious body weight loss in treated mice.
-
Animal Model:NOD/SCID (male) with Neuroendocrine prostate cancer[1]
-
Dosage:1.5 mg/kg; 3 mg/kg; 6 mg/kg
-
Administration:i.v.; single dose
-
Result:Exhibited complete tumor growth inhibition in all dose groups compared to vehicle control.
Caused no obvious body weight loss in treated mice.
-
Animal Model:BALB/c nude (female) with Small cell lung cancer[1]
-
Dosage:1 mg/kg; 3 mg/kg; 5 mg/kg
-
Administration:i.v.; weekly; 2 total doses
-
Result:Achieved tumor growth inhibition (TGI) values of 76.52% (1 mg/kg), 94.19% (3 mg/kg), and 97.13% (5 mg/kg) compared to vehicle control.
Demonstrated notably superior efficacy to lurbinectedin (23.48% TGI at 0.18 mg/kg).
Caused no obvious body weight loss in treated mice.
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 154128 (average)
-
Color Colorless to light yellow
-
SMILES
[FZ-AD005]
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FZ-AD005 Related Classifications
HY-164729 Related Classifications
Powered by Bioz